Apellis Pharmaceuticals/$APLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Ticker
$APLS
Sector
Primary listing
Employees
708
Headquarters
Website
APLS Metrics
BasicAdvanced
$3.2B
-
-$1.82
0.77
-
Price and volume
Market cap
$3.2B
Beta
0.77
52-week high
$35.71
52-week low
$16.10
Average daily volume
2.3M
Financial strength
Current ratio
3.766
Quick ratio
2.911
Long term debt to equity
295.799
Total debt to equity
300.545
Interest coverage (TTM)
-4.11%
Profitability
EBITDA (TTM)
-188.263
Gross margin (TTM)
41.59%
Net profit margin (TTM)
-30.24%
Operating margin (TTM)
-25.19%
Effective tax rate (TTM)
-0.74%
Revenue per employee (TTM)
$1,070,000
Management effectiveness
Return on assets (TTM)
-13.77%
Return on equity (TTM)
-108.49%
Valuation
Price to revenue (TTM)
4.163
Price to book
20.28
Price to tangible book (TTM)
20.28
Price to free cash flow (TTM)
711.716
Free cash flow yield (TTM)
0.14%
Free cash flow per share (TTM)
0.035
Growth
Revenue change (TTM)
20.02%
Earnings per share change (TTM)
-33.08%
3-year revenue growth (CAGR)
98.39%
3-year earnings per share growth (CAGR)
-35.11%
10-year earnings per share growth (CAGR)
-3.76%
What the Analysts think about APLS
Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.
Bulls say / Bears say
On July 28, 2025, the FDA approved EMPAVELI as the first treatment for C3 glomerulopathy and primary IC-MPGN in patients aged 12 and older, expanding Apellis’ presence into rare kidney diseases with significant unmet need.
In Q2 2025, Apellis generated $178.5 million in total revenue, including $171.4 million in U.S. net product sales, driven by SYFOVRE’s 6% quarter-over-quarter injection growth, a 55% share of new patient starts, and over 60% market share in GA.
The capped royalty purchase agreement with Sobi provides up to $300 million for 90% of ex-U.S. Empaveli royalties, strengthening Apellis’ cash position and reducing risk around international commercialization.
In Q1 2025, SYFOVRE’s 4% quarter-over-quarter injection growth was largely offset by inventory changes and funding shortages at co-pay assistance programs, highlighting challenges in converting demand into revenue.
Apellis reported a net loss of $42.2 million in Q2 2025 against cash and equivalents of $370 million, underscoring continued operating losses and a possible need for additional financing to support pipeline expansion.
In February 2025, Astellas’ Izervay received an FDA label update removing the 12-month dosing limit, which increases competition in the geographic atrophy market and threatens SYFOVRE’s market share gains.
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
APLS Financial Performance
Revenues and expenses
APLS Earnings Performance
Company profitability
APLS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apellis Pharmaceuticals stock?
Apellis Pharmaceuticals (APLS) has a market cap of $3.2B as of October 11, 2025.
What is the P/E ratio for Apellis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of October 11, 2025.
Does Apellis Pharmaceuticals stock pay dividends?
No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Apellis Pharmaceuticals dividend payment date?
Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Apellis Pharmaceuticals?
Apellis Pharmaceuticals (APLS) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.